5 The benefit-risk profile of the vaccine was considered favourable in that age group for use as a 3-dose primary series with two doses given three weeks apart followed by a third dose given at least eight weeks after the second dose Canada has approved Pfizer's Covid-19 vaccine to immunise children under the age of five. The federal health department updated information on the approved vaccines on its website saying that available data supported the effectiveness and safety of the vaccine in preventing Covid in the age group of six months through four years, reports Xinhua news agency. The benefit-risk profile of the vaccine was considered favourable in that age group for use as a 3-dose primary series with two doses given three weeks apart followed by a third dose given at least eight weeks after the second dose It's the second vaccine approved for that age group after Health Canada approved Moderna's Spikevax in July. Last week, Health Canada approved an adapted version of the Moderna Spikevax COVID-19 vaccine, known as a bivalent vaccine, to target both the original SARSCoV-2 virus and the Omicron (BA.1) variant as a booster dose in individuals aged 18 and above.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!